(Q27853332)

English

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

PubMed publication ID

13 November 2016

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial (English)

1 reference

PubMed publication ID

13 November 2016

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Martine Piccart-Gebhart

19

object named as

Martine Piccart-Gebhart

0 references

1

object named as

Nadia Harbeck

0 references

Chiun-Sheng Huang

object named as

Chiun-Sheng Huang

2

0 references

Marek Wojtukiewicz

object named as

Marek Wojtukiewicz

13

0 references

10

object named as

Jacek Jassem

0 references

6

object named as

Seock-Ah Im

0 references

author name string

Sara Hurvitz

3

0 references

Dah-Cherng Yeh

4

0 references

Zhimin Shao

5

0 references

Kyung Hae Jung

7

0 references

Kunwei Shen

8

0 references

Jungsil Ro

9

0 references

Qingyuan Zhang

11

0 references

Young-Hyuck Im

12

0 references

Qiang Sun

14

0 references

Shin-Cheh Chen

15

0 references

Rainer-Georg Goeldner

16

0 references

Martina Uttenreuther-Fischer

17

0 references

Binghe Xu

18

0 references

language of work or name

1 reference

based on heuristic

inferred from title

publication date

March 2016

0 references

Lancet Oncology Commission

0 references

17

0 references

3

0 references

357-66

0 references

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Afatinib in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Median follow-up in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900540-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00540-9

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27853332&oldid=1686981918"